{"gene":"HSD17B11","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2003,"finding":"HSD17B11 (17β-HSDXI) catalyzes the conversion of 5α-androstane-3α,17β-diol to androsterone, establishing its enzymatic activity as a 17β-hydroxysteroid dehydrogenase acting on androgen substrates. cAMP down-regulates its enzymatic activity and reduces gene expression in mouse Y1 cells.","method":"Enzyme activity assay in transfected cells; Northern blot; immunohistochemistry; promoter analysis identifying SF-1 half-sites","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic assay with defined substrate/product, replicated across multiple cell and tissue systems, multiple orthogonal methods in one study","pmids":["12697717"],"is_preprint":false},{"year":1998,"finding":"HSD17B11 (Pan1b) acts as a dehydrogenase on 17β-hydroxysteroids but does not metabolize glucocorticoids, identifying it as a novel 17β-HSD family member of the short-chain alcohol dehydrogenase superfamily.","method":"Expression in CHO cells (CHOP) with substrate metabolism assays; Northern blot","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional enzymatic assay in heterologous cells with substrate panel, single lab, but conclusions partially confounded by endogenous oxidoreductase activity noted by authors","pmids":["9888557"],"is_preprint":false},{"year":2015,"finding":"HSD17B11 (DHRS8/SDR16C2) is an integral endoplasmic reticulum membrane protein with cytosolic orientation and catalyzes NAD+-dependent oxidation of β-estradiol, testosterone, methyltestosterone, nandrolone, and all-trans-retinol in vitro, with defined Km and Vmax values for β-estradiol (Km=39.86 µM) and testosterone (Km=1207.29 µM).","method":"Recombinant protein expression; in vitro enzyme kinetics assay; membrane topology determination","journal":"Molecular and cellular biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with recombinant enzyme, kinetic parameters measured, membrane topology demonstrated, single lab but multiple orthogonal methods","pmids":["26472732"],"is_preprint":false},{"year":2011,"finding":"HSD17B11 transcription in prostate cancer cells is regulated by Sp1 and C/EBPα binding to sites within the proximal promoter region (-107/+18). Mutagenesis of Sp1 and C/EBP binding sites abolished promoter activity, and specific recruitment of Sp1 and C/EBPα to the HSD17B11 promoter was confirmed by DAPA and ChIP assays.","method":"Transfection with promoter-reporter constructs; site-directed mutagenesis; DAPA; ChIP assay","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis combined with ChIP and DAPA validating transcription factor binding, two orthogonal methods, single lab","pmids":["21549806"],"is_preprint":false},{"year":2010,"finding":"Ectopic expression of C/EBPα or C/EBPβ induces HSD17B11 expression in HepG2 hepatocarcinoma cells, but gene reporter assays showed this induction is not mediated by the CCAAT boxes in the proximal promoter of HSD17B11.","method":"Ectopic expression of C/EBP isoforms; gene reporter assay; promoter analysis","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with mutagenesis context, two orthogonal methods, single lab","pmids":["20638476"],"is_preprint":false},{"year":2018,"finding":"HSD17B11 localizes to lipid droplets (LDs) in adrenal cells, as demonstrated by proteomics analysis of isolated LD fractions from human, macaque, and rodent adrenal glands confirmed by Western blot and subcellular localization experiments, suggesting LDs are sites of steroid hormone metabolism.","method":"LD proteomics (mass spectrometry); Western blot of fractionated LDs; subcellular localization imaging","journal":"Proteomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation confirmed by Western blot and imaging across multiple species, single lab","pmids":["30358111"],"is_preprint":false},{"year":2022,"finding":"HSD17B11 bioactivates lipidic alkynylcarbinols (dialkynylcarbinols) by oxidizing the carbinol center to generate dialkynylketones, which are protein-reactive electrophiles that covalently modify proteins involved in protein quality control (via Michael addition on cysteines and lysines), causing ER stress, unfolded protein response activation, ubiquitin-proteasome system inhibition, and apoptosis. This was discovered through a genetic screen in haploid human cells.","method":"Genetic screen in haploid human cells; in vitro enzymatic oxidation assay; mass spectrometry characterization of adducts; ER stress and UPS functional assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic screen, in vitro enzymatic assay, chemical characterization of products, and multiple downstream cellular assays, single lab but highly orthogonal methods","pmids":["35535493"],"is_preprint":false},{"year":2023,"finding":"HSD17B11 specifically bioactivates phenyl dialkynylcarbinol (PAC) prodrugs via enantiospecific oxidation of the carbinol to ynones, which then covalently modify cellular proteins leading to ER stress and apoptosis. Docking studies using an AlphaFold model of HSD17B11 provided a molecular basis for substrate recognition. Selectivity between HSD17B11 and its paralogue HSD17B13 for prodrug bioactivation was characterized.","method":"Clickable probe/activity-based protein profiling; cell viability assays with HSD17B11-expressing cells; AlphaFold model docking; enantioselective synthesis and testing","journal":"Journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional assay with clickable probe confirming bioactivation, docking is computational (Tier 4) but supported by experimental data, single lab","pmids":["37816126"],"is_preprint":false},{"year":2020,"finding":"A CRISPR-Cas9 genome-wide knockout screen identified HSD17B11 as a mediator of the selective cytotoxic effects of dehydrofalcarinol in MDA-MB-231 mesenchymal stem-like triple-negative breast cancer cells, which express high levels of HSD17B11.","method":"CRISPR-Cas9 genome-wide knockout screen; cytotoxicity assays","journal":"Journal of natural products","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide CRISPR screen with defined phenotypic readout, single lab, mechanistic follow-up limited in this paper","pmids":["33021790"],"is_preprint":false},{"year":2024,"finding":"HSD17B11 was identified as an interaction partner of GCKIII kinases (MST3, STK25, MST4) by genome-wide yeast two-hybrid screen of a human hepatocyte library, and controls their action in hepatocellular lipid homeostasis via a conformational change mechanism.","method":"Yeast two-hybrid screen; functional lipid content assays following knockdown","journal":"Journal of lipid research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid interaction identified but mechanistic detail of conformational change is not directly demonstrated in the abstract, single lab","pmids":["39395791"],"is_preprint":false},{"year":2022,"finding":"FTO demethylase promotes HSD17B11 expression by removing m6A modifications on HSD17B11 mRNA; depleting the m6A reader YTHDF1 increases HSD17B11 protein levels, indicating YTHDF1 negatively regulates HSD17B11 translation. Increased HSD17B11 promotes lipid droplet formation in esophageal cancer cells.","method":"meRIP-seq; transcriptome analysis; siRNA knockdown; overexpression; lipid droplet staining","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — meRIP-seq identifies m6A on HSD17B11 mRNA, functional validation with YTHDF1 depletion and lipid droplet formation assay, single lab","pmids":["35568876"],"is_preprint":false},{"year":2026,"finding":"HSD17B11 physically interacts with ferroptosis suppressor protein 1 (FSP1) on lipid droplets and is required to maintain FSP1 association with LDs and total cellular FSP1 abundance. HSD17B11 deficiency reduces LD-associated and total FSP1 levels and increases cellular sensitivity to lipid oxidative stress. Both FSP1 N-myristoylation and an intact HSD17B11 interaction interface are necessary for FSP1 LD targeting.","method":"Silver staining and mass spectrometry of purified LD proteins; immunoblotting; imaging; mutational analysis; lipid oxidative stress assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (MS, immunoblot, imaging, mutagenesis), preprint not yet peer-reviewed, single lab","pmids":["42239065"],"is_preprint":true}],"current_model":"HSD17B11 is an endoplasmic reticulum-anchored short-chain dehydrogenase/reductase (SDR) that localizes to lipid droplets and catalyzes NAD+-dependent oxidation of 17β-hydroxysteroids (including 5α-androstane-3α,17β-diol to androsterone, estradiol, and testosterone); it also bioactivates lipidic alkynylcarbinol prodrugs by oxidizing the carbinol to reactive ynone electrophiles that cause ER stress and apoptosis; on lipid droplets it physically interacts with the anti-ferroptotic protein FSP1 and is required to maintain FSP1 LD localization and cellular ferroptosis defense; its transcription is regulated by Sp1 and C/EBPα in prostate cancer cells, and its mRNA is subject to m6A-mediated translational regulation via FTO/YTHDF1."},"narrative":{"mechanistic_narrative":"HSD17B11 is an endoplasmic reticulum-anchored short-chain dehydrogenase/reductase that oxidizes 17β-hydroxysteroids and contributes to cellular lipid homeostasis [PMID:12697717, PMID:26472732]. Functioning as a NAD+-dependent enzyme, it converts 5α-androstane-3α,17β-diol to androsterone and oxidizes β-estradiol, testosterone, and additional steroid and retinoid substrates with defined kinetics, acting on 17β-hydroxysteroids but not glucocorticoids [PMID:12697717, PMID:26472732]. The protein is an integral ER membrane protein of cytosolic orientation and also localizes to lipid droplets in steroidogenic cells, positioning these organelles as sites of steroid metabolism [PMID:26472732, PMID:30358111]. On lipid droplets, HSD17B11 physically interacts with the anti-ferroptotic protein FSP1 and is required to maintain FSP1 lipid droplet association and total FSP1 abundance, such that its loss increases sensitivity to lipid oxidative stress [PMID:42239065]. Independently, HSD17B11 bioactivates lipidic alkynylcarbinol prodrugs by oxidizing the carbinol center to reactive ynone electrophiles that covalently modify proteins, triggering ER stress, unfolded protein response, proteasome inhibition, and apoptosis, a property exploited for selective cytotoxicity in cancer cells expressing the enzyme [PMID:35535493, PMID:37816126, PMID:33021790]. Its expression is controlled at the transcriptional level by Sp1 and C/EBPα binding the proximal promoter [PMID:21549806] and post-transcriptionally by m6A modification through FTO and the reader YTHDF1 [PMID:35568876].","teleology":[{"year":1998,"claim":"Established HSD17B11 as a distinct member of the short-chain alcohol dehydrogenase superfamily acting on 17β-hydroxysteroids, defining its enzyme class and substrate selectivity.","evidence":"Heterologous expression in CHO cells with a substrate metabolism panel and Northern blot","pmids":["9888557"],"confidence":"Medium","gaps":["Endogenous oxidoreductase activity confounded substrate assignment","No kinetic parameters or product identification","Physiological substrate not established"]},{"year":2003,"claim":"Defined a specific androgen-metabolizing reaction and its hormonal regulation, anchoring HSD17B11 in steroidogenesis.","evidence":"Enzyme activity assay in transfected cells with defined substrate/product, Northern blot, immunohistochemistry, and promoter analysis","pmids":["12697717"],"confidence":"High","gaps":["Direction of catalysis in vivo (oxidative vs reductive) not resolved","Tissue-specific physiological role not defined"]},{"year":2010,"claim":"Linked HSD17B11 expression to C/EBP transcription factors but showed the induction is not mediated by proximal CCAAT boxes, refining the regulatory model.","evidence":"Ectopic C/EBP isoform expression with gene reporter and promoter analysis in HepG2 cells","pmids":["20638476"],"confidence":"Medium","gaps":["Actual cis-element mediating C/EBP induction not identified","Single hepatocarcinoma cell context"]},{"year":2011,"claim":"Mapped direct transcription-factor occupancy of the HSD17B11 promoter, establishing Sp1 and C/EBPα as drivers of its expression in prostate cancer.","evidence":"Promoter-reporter constructs with site-directed mutagenesis, DAPA, and ChIP","pmids":["21549806"],"confidence":"High","gaps":["Upstream signals controlling Sp1/C/EBPα recruitment unknown","Relevance to non-prostate tissues not tested"]},{"year":2015,"claim":"Reconstituted catalysis with recombinant enzyme and defined membrane topology, establishing HSD17B11 as a cytosolically oriented ER enzyme with measured substrate kinetics.","evidence":"Recombinant protein expression, in vitro enzyme kinetics, and membrane topology determination","pmids":["26472732"],"confidence":"High","gaps":["High Km for testosterone questions physiological substrate","Cofactor preference in vivo not addressed"]},{"year":2018,"claim":"Localized HSD17B11 to lipid droplets across multiple species, implicating these organelles as steroid metabolism sites and expanding its subcellular context beyond the ER.","evidence":"Lipid droplet proteomics by mass spectrometry, Western blot of fractionated LDs, and subcellular imaging","pmids":["30358111"],"confidence":"Medium","gaps":["Mechanism of LD targeting not defined","Functional consequence of LD localization not tested in this study"]},{"year":2020,"claim":"Identified HSD17B11 in an unbiased screen as the determinant of dehydrofalcarinol cytotoxicity, revealing a prodrug-bioactivation function.","evidence":"Genome-wide CRISPR-Cas9 knockout screen with cytotoxicity readout in TNBC cells","pmids":["33021790"],"confidence":"Medium","gaps":["Bioactivation mechanism not resolved in this study","Limited mechanistic follow-up"]},{"year":2022,"claim":"Established the chemical mechanism of prodrug bioactivation, showing HSD17B11 oxidizes alkynylcarbinols to protein-reactive ynones that trigger ER stress and apoptosis.","evidence":"Haploid genetic screen, in vitro enzymatic oxidation, mass spectrometry of adducts, and ER stress/UPS functional assays","pmids":["35535493"],"confidence":"High","gaps":["Endogenous physiological substrate distinct from prodrugs not identified","Range of modified protein targets incompletely defined"]},{"year":2022,"claim":"Revealed post-transcriptional control of HSD17B11 by m6A, with FTO promoting and YTHDF1 repressing its expression, and linked elevated HSD17B11 to lipid droplet formation.","evidence":"meRIP-seq, siRNA knockdown, overexpression, and lipid droplet staining in esophageal cancer cells","pmids":["35568876"],"confidence":"Medium","gaps":["Mechanistic basis for LD induction by HSD17B11 not defined","Single cancer context"]},{"year":2023,"claim":"Refined prodrug bioactivation with enantiospecific ynone generation and distinguished HSD17B11 from its paralogue HSD17B13, providing a structural rationale for substrate recognition.","evidence":"Activity-based protein profiling, cell viability assays, AlphaFold model docking, and enantioselective synthesis","pmids":["37816126"],"confidence":"Medium","gaps":["Docking is computational without experimental structure","Active-site residues governing selectivity not mutationally validated"]},{"year":2024,"claim":"Proposed a non-catalytic interaction role in which HSD17B11 binds GCKIII kinases to control hepatocellular lipid homeostasis.","evidence":"Genome-wide yeast two-hybrid screen of a hepatocyte library and lipid content assays following knockdown","pmids":["39395791"],"confidence":"Low","gaps":["Interaction from yeast two-hybrid not validated by reciprocal co-IP in mammalian cells","Conformational change mechanism not directly demonstrated"]},{"year":2026,"claim":"Connected HSD17B11 to ferroptosis defense by showing it scaffolds FSP1 on lipid droplets and sustains FSP1 abundance, protecting against lipid oxidative stress.","evidence":"Lipid droplet protein purification with MS, immunoblotting, imaging, mutational analysis, and lipid oxidative stress assays","pmids":["42239065"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Whether enzymatic activity is required for FSP1 maintenance unresolved","Structural basis of the HSD17B11-FSP1 interface not determined"]},{"year":null,"claim":"The endogenous physiological substrate and the direction of catalysis in vivo remain unresolved, as does whether HSD17B11's catalytic activity is required for its lipid-droplet scaffolding roles.","evidence":"No timeline study reconciles the in vitro steroid/retinoid activities with a defined in vivo metabolic role or links catalysis to the FSP1/GCKIII functions","pmids":[],"confidence":"Low","gaps":["No knockout-phenotype linking enzymatic activity to organismal steroid or lipid metabolism","Mechanism coupling LD localization to FSP1 stability undefined","No experimentally determined structure"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2,6]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[6,7]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[5,10,11]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,10]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[6,11]}],"complexes":[],"partners":["FSP1","MST3","STK25","MST4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8NBQ5","full_name":"Estradiol 17-beta-dehydrogenase 11","aliases":["17-beta-hydroxysteroid dehydrogenase 11","17-beta-HSD 11","17bHSD11","17betaHSD11","17-beta-hydroxysteroid dehydrogenase XI","17-beta-HSD XI","17betaHSDXI","Cutaneous T-cell lymphoma-associated antigen HD-CL-03","CTCL-associated antigen HD-CL-03","Dehydrogenase/reductase SDR family member 8","Retinal short-chain dehydrogenase/reductase 2","retSDR2","Short chain dehydrogenase/reductase family 16C member 2"],"length_aa":300,"mass_kda":33.0,"function":"Can convert androstan-3-alpha,17-beta-diol (3-alpha-diol) to androsterone in vitro, suggesting that it may participate in androgen metabolism during steroidogenesis. May act by metabolizing compounds that stimulate steroid synthesis and/or by generating metabolites that inhibit it. Has no activity toward DHEA (dehydroepiandrosterone), or A-dione (4-androste-3,17-dione), and only a slight activity toward testosterone to A-dione. Tumor-associated antigen in cutaneous T-cell lymphoma","subcellular_location":"Endoplasmic reticulum; Lipid droplet","url":"https://www.uniprot.org/uniprotkb/Q8NBQ5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HSD17B11","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"COPA","stoichiometry":0.2},{"gene":"COPB2","stoichiometry":0.2},{"gene":"COPE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/HSD17B11","total_profiled":1310},"omim":[{"mim_id":"612831","title":"17-@BETA-HYDROXYSTEROID DEHYDROGENASE XI; HSD17B11","url":"https://www.omim.org/entry/612831"},{"mim_id":"612127","title":"17-@BETA-HYDROXYSTEROID DEHYDROGENASE XIII; HSD17B13","url":"https://www.omim.org/entry/612127"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Lipid droplets","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"intestine","ntpm":271.8},{"tissue":"liver","ntpm":225.9}],"url":"https://www.proteinatlas.org/search/HSD17B11"},"hgnc":{"alias_symbol":["RetSDR2","17-BETA-HSD11","17-BETA-HSDXI","PAN1B","SDR16C2"],"prev_symbol":["DHRS8"]},"alphafold":{"accession":"Q8NBQ5","domains":[{"cath_id":"3.40.50.720","chopping":"34-286","consensus_level":"high","plddt":94.7187,"start":34,"end":286}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NBQ5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NBQ5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NBQ5-F1-predicted_aligned_error_v6.png","plddt_mean":93.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HSD17B11","jax_strain_url":"https://www.jax.org/strain/search?query=HSD17B11"},"sequence":{"accession":"Q8NBQ5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8NBQ5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8NBQ5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NBQ5"}},"corpus_meta":[{"pmid":"12697717","id":"PMC_12697717","title":"17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells.","date":"2003","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12697717","citation_count":59,"is_preprint":false},{"pmid":"35568876","id":"PMC_35568876","title":"m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer.","date":"2022","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/35568876","citation_count":55,"is_preprint":false},{"pmid":"9888557","id":"PMC_9888557","title":"Cloning and expression of a novel tissue specific 17beta-hydroxysteroid dehydrogenase.","date":"1998","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/9888557","citation_count":31,"is_preprint":false},{"pmid":"30358111","id":"PMC_30358111","title":"The Adrenal Lipid Droplet is a New Site for Steroid Hormone Metabolism.","date":"2018","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/30358111","citation_count":23,"is_preprint":false},{"pmid":"32595704","id":"PMC_32595704","title":"Lnc-HSD17B11-1:1 Functions as a Competing Endogenous RNA to Promote Colorectal Cancer Progression by Sponging miR-338-3p to Upregulate MACC1.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32595704","citation_count":20,"is_preprint":false},{"pmid":"20638476","id":"PMC_20638476","title":"Type 10 17β-hydroxysteroid dehydrogenase expression is regulated by C/EBPβ in HepG2 cells.","date":"2010","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20638476","citation_count":14,"is_preprint":false},{"pmid":"36135372","id":"PMC_36135372","title":"Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment.","date":"2022","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/36135372","citation_count":14,"is_preprint":false},{"pmid":"33021790","id":"PMC_33021790","title":"CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells.","date":"2020","source":"Journal of natural products","url":"https://pubmed.ncbi.nlm.nih.gov/33021790","citation_count":14,"is_preprint":false},{"pmid":"30407918","id":"PMC_30407918","title":"Identification and characterization of ERV transcripts in goat embryos.","date":"2019","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30407918","citation_count":11,"is_preprint":false},{"pmid":"37511041","id":"PMC_37511041","title":"Epigenomics Analysis of the Suppression Role of SIRT1 via H3K9 Deacetylation in Preadipocyte Differentiation.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37511041","citation_count":11,"is_preprint":false},{"pmid":"19469652","id":"PMC_19469652","title":"17beta-hydroxysteroid dehydrogenase type 11 (Pan1b) expression in human prostate cancer.","date":"2009","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/19469652","citation_count":10,"is_preprint":false},{"pmid":"37086619","id":"PMC_37086619","title":"G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37086619","citation_count":8,"is_preprint":false},{"pmid":"21549806","id":"PMC_21549806","title":"Transcriptional regulation of type 11 17β-hydroxysteroid dehydrogenase expression in prostate cancer cells.","date":"2011","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21549806","citation_count":7,"is_preprint":false},{"pmid":"37816126","id":"PMC_37816126","title":"Phenyl dialkynylcarbinols, a Bioinspired Series of Synthetic Antitumor Acetylenic Lipids.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37816126","citation_count":5,"is_preprint":false},{"pmid":"35535493","id":"PMC_35535493","title":"SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35535493","citation_count":5,"is_preprint":false},{"pmid":"39395791","id":"PMC_39395791","title":"GCKIII kinases control hepatocellular lipid homeostasis via shared mode of action.","date":"2024","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/39395791","citation_count":4,"is_preprint":false},{"pmid":"26472732","id":"PMC_26472732","title":"Human dehydrogenase/reductase (SDR family) member 8 (DHRS8): a description and evaluation of its biochemical properties.","date":"2015","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26472732","citation_count":4,"is_preprint":false},{"pmid":"35690242","id":"PMC_35690242","title":"Differential proteomics analysis of JEG-3 and JAR placental cell models and the effect of androgen treatment.","date":"2022","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35690242","citation_count":3,"is_preprint":false},{"pmid":"37782778","id":"PMC_37782778","title":"Identification of ferroptotic genes and phenotypes in idiopathic nonobstructive azoospermia.","date":"2023","source":"Systems biology in reproductive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37782778","citation_count":3,"is_preprint":false},{"pmid":"40299520","id":"PMC_40299520","title":"Exploring Immune-Related Ferroptosis Genes in Thyroid Cancer: A Comprehensive Analysis.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/40299520","citation_count":1,"is_preprint":false},{"pmid":"42239065","id":"PMC_42239065","title":"HSD17B11 maintains FSP1 localization on lipid droplets to support ferroptosis defense.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/42239065","citation_count":0,"is_preprint":false},{"pmid":"41029168","id":"PMC_41029168","title":"Exploring therapeutic targets for hepatocellular carcinoma through druggable genes.","date":"2025","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41029168","citation_count":0,"is_preprint":false},{"pmid":"41407026","id":"PMC_41407026","title":"Decipher the molecular network of PFOA in inflammatory bowel disease through integrating machine learning, molecular docking strategies, and validation in vitro.","date":"2025","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/41407026","citation_count":0,"is_preprint":false},{"pmid":"41541230","id":"PMC_41541230","title":"A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non-small-cell lung cancer.","date":"2026","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41541230","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15406,"output_tokens":3093,"usd":0.046307,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10592,"output_tokens":3705,"usd":0.072792,"stage2_stop_reason":"end_turn"},"total_usd":0.119099,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"HSD17B11 (17β-HSDXI) catalyzes the conversion of 5α-androstane-3α,17β-diol to androsterone, establishing its enzymatic activity as a 17β-hydroxysteroid dehydrogenase acting on androgen substrates. cAMP down-regulates its enzymatic activity and reduces gene expression in mouse Y1 cells.\",\n      \"method\": \"Enzyme activity assay in transfected cells; Northern blot; immunohistochemistry; promoter analysis identifying SF-1 half-sites\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic assay with defined substrate/product, replicated across multiple cell and tissue systems, multiple orthogonal methods in one study\",\n      \"pmids\": [\"12697717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HSD17B11 (Pan1b) acts as a dehydrogenase on 17β-hydroxysteroids but does not metabolize glucocorticoids, identifying it as a novel 17β-HSD family member of the short-chain alcohol dehydrogenase superfamily.\",\n      \"method\": \"Expression in CHO cells (CHOP) with substrate metabolism assays; Northern blot\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional enzymatic assay in heterologous cells with substrate panel, single lab, but conclusions partially confounded by endogenous oxidoreductase activity noted by authors\",\n      \"pmids\": [\"9888557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HSD17B11 (DHRS8/SDR16C2) is an integral endoplasmic reticulum membrane protein with cytosolic orientation and catalyzes NAD+-dependent oxidation of β-estradiol, testosterone, methyltestosterone, nandrolone, and all-trans-retinol in vitro, with defined Km and Vmax values for β-estradiol (Km=39.86 µM) and testosterone (Km=1207.29 µM).\",\n      \"method\": \"Recombinant protein expression; in vitro enzyme kinetics assay; membrane topology determination\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with recombinant enzyme, kinetic parameters measured, membrane topology demonstrated, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26472732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HSD17B11 transcription in prostate cancer cells is regulated by Sp1 and C/EBPα binding to sites within the proximal promoter region (-107/+18). Mutagenesis of Sp1 and C/EBP binding sites abolished promoter activity, and specific recruitment of Sp1 and C/EBPα to the HSD17B11 promoter was confirmed by DAPA and ChIP assays.\",\n      \"method\": \"Transfection with promoter-reporter constructs; site-directed mutagenesis; DAPA; ChIP assay\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis combined with ChIP and DAPA validating transcription factor binding, two orthogonal methods, single lab\",\n      \"pmids\": [\"21549806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ectopic expression of C/EBPα or C/EBPβ induces HSD17B11 expression in HepG2 hepatocarcinoma cells, but gene reporter assays showed this induction is not mediated by the CCAAT boxes in the proximal promoter of HSD17B11.\",\n      \"method\": \"Ectopic expression of C/EBP isoforms; gene reporter assay; promoter analysis\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with mutagenesis context, two orthogonal methods, single lab\",\n      \"pmids\": [\"20638476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HSD17B11 localizes to lipid droplets (LDs) in adrenal cells, as demonstrated by proteomics analysis of isolated LD fractions from human, macaque, and rodent adrenal glands confirmed by Western blot and subcellular localization experiments, suggesting LDs are sites of steroid hormone metabolism.\",\n      \"method\": \"LD proteomics (mass spectrometry); Western blot of fractionated LDs; subcellular localization imaging\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation confirmed by Western blot and imaging across multiple species, single lab\",\n      \"pmids\": [\"30358111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HSD17B11 bioactivates lipidic alkynylcarbinols (dialkynylcarbinols) by oxidizing the carbinol center to generate dialkynylketones, which are protein-reactive electrophiles that covalently modify proteins involved in protein quality control (via Michael addition on cysteines and lysines), causing ER stress, unfolded protein response activation, ubiquitin-proteasome system inhibition, and apoptosis. This was discovered through a genetic screen in haploid human cells.\",\n      \"method\": \"Genetic screen in haploid human cells; in vitro enzymatic oxidation assay; mass spectrometry characterization of adducts; ER stress and UPS functional assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic screen, in vitro enzymatic assay, chemical characterization of products, and multiple downstream cellular assays, single lab but highly orthogonal methods\",\n      \"pmids\": [\"35535493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HSD17B11 specifically bioactivates phenyl dialkynylcarbinol (PAC) prodrugs via enantiospecific oxidation of the carbinol to ynones, which then covalently modify cellular proteins leading to ER stress and apoptosis. Docking studies using an AlphaFold model of HSD17B11 provided a molecular basis for substrate recognition. Selectivity between HSD17B11 and its paralogue HSD17B13 for prodrug bioactivation was characterized.\",\n      \"method\": \"Clickable probe/activity-based protein profiling; cell viability assays with HSD17B11-expressing cells; AlphaFold model docking; enantioselective synthesis and testing\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional assay with clickable probe confirming bioactivation, docking is computational (Tier 4) but supported by experimental data, single lab\",\n      \"pmids\": [\"37816126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A CRISPR-Cas9 genome-wide knockout screen identified HSD17B11 as a mediator of the selective cytotoxic effects of dehydrofalcarinol in MDA-MB-231 mesenchymal stem-like triple-negative breast cancer cells, which express high levels of HSD17B11.\",\n      \"method\": \"CRISPR-Cas9 genome-wide knockout screen; cytotoxicity assays\",\n      \"journal\": \"Journal of natural products\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide CRISPR screen with defined phenotypic readout, single lab, mechanistic follow-up limited in this paper\",\n      \"pmids\": [\"33021790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HSD17B11 was identified as an interaction partner of GCKIII kinases (MST3, STK25, MST4) by genome-wide yeast two-hybrid screen of a human hepatocyte library, and controls their action in hepatocellular lipid homeostasis via a conformational change mechanism.\",\n      \"method\": \"Yeast two-hybrid screen; functional lipid content assays following knockdown\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid interaction identified but mechanistic detail of conformational change is not directly demonstrated in the abstract, single lab\",\n      \"pmids\": [\"39395791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FTO demethylase promotes HSD17B11 expression by removing m6A modifications on HSD17B11 mRNA; depleting the m6A reader YTHDF1 increases HSD17B11 protein levels, indicating YTHDF1 negatively regulates HSD17B11 translation. Increased HSD17B11 promotes lipid droplet formation in esophageal cancer cells.\",\n      \"method\": \"meRIP-seq; transcriptome analysis; siRNA knockdown; overexpression; lipid droplet staining\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — meRIP-seq identifies m6A on HSD17B11 mRNA, functional validation with YTHDF1 depletion and lipid droplet formation assay, single lab\",\n      \"pmids\": [\"35568876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"HSD17B11 physically interacts with ferroptosis suppressor protein 1 (FSP1) on lipid droplets and is required to maintain FSP1 association with LDs and total cellular FSP1 abundance. HSD17B11 deficiency reduces LD-associated and total FSP1 levels and increases cellular sensitivity to lipid oxidative stress. Both FSP1 N-myristoylation and an intact HSD17B11 interaction interface are necessary for FSP1 LD targeting.\",\n      \"method\": \"Silver staining and mass spectrometry of purified LD proteins; immunoblotting; imaging; mutational analysis; lipid oxidative stress assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (MS, immunoblot, imaging, mutagenesis), preprint not yet peer-reviewed, single lab\",\n      \"pmids\": [\"42239065\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"HSD17B11 is an endoplasmic reticulum-anchored short-chain dehydrogenase/reductase (SDR) that localizes to lipid droplets and catalyzes NAD+-dependent oxidation of 17β-hydroxysteroids (including 5α-androstane-3α,17β-diol to androsterone, estradiol, and testosterone); it also bioactivates lipidic alkynylcarbinol prodrugs by oxidizing the carbinol to reactive ynone electrophiles that cause ER stress and apoptosis; on lipid droplets it physically interacts with the anti-ferroptotic protein FSP1 and is required to maintain FSP1 LD localization and cellular ferroptosis defense; its transcription is regulated by Sp1 and C/EBPα in prostate cancer cells, and its mRNA is subject to m6A-mediated translational regulation via FTO/YTHDF1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HSD17B11 is an endoplasmic reticulum-anchored short-chain dehydrogenase/reductase that oxidizes 17β-hydroxysteroids and contributes to cellular lipid homeostasis [#0, #2]. Functioning as a NAD+-dependent enzyme, it converts 5α-androstane-3α,17β-diol to androsterone and oxidizes β-estradiol, testosterone, and additional steroid and retinoid substrates with defined kinetics, acting on 17β-hydroxysteroids but not glucocorticoids [#0, #2]. The protein is an integral ER membrane protein of cytosolic orientation and also localizes to lipid droplets in steroidogenic cells, positioning these organelles as sites of steroid metabolism [#2, #5]. On lipid droplets, HSD17B11 physically interacts with the anti-ferroptotic protein FSP1 and is required to maintain FSP1 lipid droplet association and total FSP1 abundance, such that its loss increases sensitivity to lipid oxidative stress [#11]. Independently, HSD17B11 bioactivates lipidic alkynylcarbinol prodrugs by oxidizing the carbinol center to reactive ynone electrophiles that covalently modify proteins, triggering ER stress, unfolded protein response, proteasome inhibition, and apoptosis, a property exploited for selective cytotoxicity in cancer cells expressing the enzyme [#6, #7, #8]. Its expression is controlled at the transcriptional level by Sp1 and C/EBPα binding the proximal promoter [#3] and post-transcriptionally by m6A modification through FTO and the reader YTHDF1 [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established HSD17B11 as a distinct member of the short-chain alcohol dehydrogenase superfamily acting on 17β-hydroxysteroids, defining its enzyme class and substrate selectivity.\",\n      \"evidence\": \"Heterologous expression in CHO cells with a substrate metabolism panel and Northern blot\",\n      \"pmids\": [\"9888557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous oxidoreductase activity confounded substrate assignment\", \"No kinetic parameters or product identification\", \"Physiological substrate not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined a specific androgen-metabolizing reaction and its hormonal regulation, anchoring HSD17B11 in steroidogenesis.\",\n      \"evidence\": \"Enzyme activity assay in transfected cells with defined substrate/product, Northern blot, immunohistochemistry, and promoter analysis\",\n      \"pmids\": [\"12697717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direction of catalysis in vivo (oxidative vs reductive) not resolved\", \"Tissue-specific physiological role not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked HSD17B11 expression to C/EBP transcription factors but showed the induction is not mediated by proximal CCAAT boxes, refining the regulatory model.\",\n      \"evidence\": \"Ectopic C/EBP isoform expression with gene reporter and promoter analysis in HepG2 cells\",\n      \"pmids\": [\"20638476\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Actual cis-element mediating C/EBP induction not identified\", \"Single hepatocarcinoma cell context\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapped direct transcription-factor occupancy of the HSD17B11 promoter, establishing Sp1 and C/EBPα as drivers of its expression in prostate cancer.\",\n      \"evidence\": \"Promoter-reporter constructs with site-directed mutagenesis, DAPA, and ChIP\",\n      \"pmids\": [\"21549806\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals controlling Sp1/C/EBPα recruitment unknown\", \"Relevance to non-prostate tissues not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Reconstituted catalysis with recombinant enzyme and defined membrane topology, establishing HSD17B11 as a cytosolically oriented ER enzyme with measured substrate kinetics.\",\n      \"evidence\": \"Recombinant protein expression, in vitro enzyme kinetics, and membrane topology determination\",\n      \"pmids\": [\"26472732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High Km for testosterone questions physiological substrate\", \"Cofactor preference in vivo not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Localized HSD17B11 to lipid droplets across multiple species, implicating these organelles as steroid metabolism sites and expanding its subcellular context beyond the ER.\",\n      \"evidence\": \"Lipid droplet proteomics by mass spectrometry, Western blot of fractionated LDs, and subcellular imaging\",\n      \"pmids\": [\"30358111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of LD targeting not defined\", \"Functional consequence of LD localization not tested in this study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified HSD17B11 in an unbiased screen as the determinant of dehydrofalcarinol cytotoxicity, revealing a prodrug-bioactivation function.\",\n      \"evidence\": \"Genome-wide CRISPR-Cas9 knockout screen with cytotoxicity readout in TNBC cells\",\n      \"pmids\": [\"33021790\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Bioactivation mechanism not resolved in this study\", \"Limited mechanistic follow-up\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established the chemical mechanism of prodrug bioactivation, showing HSD17B11 oxidizes alkynylcarbinols to protein-reactive ynones that trigger ER stress and apoptosis.\",\n      \"evidence\": \"Haploid genetic screen, in vitro enzymatic oxidation, mass spectrometry of adducts, and ER stress/UPS functional assays\",\n      \"pmids\": [\"35535493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological substrate distinct from prodrugs not identified\", \"Range of modified protein targets incompletely defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed post-transcriptional control of HSD17B11 by m6A, with FTO promoting and YTHDF1 repressing its expression, and linked elevated HSD17B11 to lipid droplet formation.\",\n      \"evidence\": \"meRIP-seq, siRNA knockdown, overexpression, and lipid droplet staining in esophageal cancer cells\",\n      \"pmids\": [\"35568876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic basis for LD induction by HSD17B11 not defined\", \"Single cancer context\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Refined prodrug bioactivation with enantiospecific ynone generation and distinguished HSD17B11 from its paralogue HSD17B13, providing a structural rationale for substrate recognition.\",\n      \"evidence\": \"Activity-based protein profiling, cell viability assays, AlphaFold model docking, and enantioselective synthesis\",\n      \"pmids\": [\"37816126\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Docking is computational without experimental structure\", \"Active-site residues governing selectivity not mutationally validated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Proposed a non-catalytic interaction role in which HSD17B11 binds GCKIII kinases to control hepatocellular lipid homeostasis.\",\n      \"evidence\": \"Genome-wide yeast two-hybrid screen of a hepatocyte library and lipid content assays following knockdown\",\n      \"pmids\": [\"39395791\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Interaction from yeast two-hybrid not validated by reciprocal co-IP in mammalian cells\", \"Conformational change mechanism not directly demonstrated\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Connected HSD17B11 to ferroptosis defense by showing it scaffolds FSP1 on lipid droplets and sustains FSP1 abundance, protecting against lipid oxidative stress.\",\n      \"evidence\": \"Lipid droplet protein purification with MS, immunoblotting, imaging, mutational analysis, and lipid oxidative stress assays\",\n      \"pmids\": [\"42239065\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Whether enzymatic activity is required for FSP1 maintenance unresolved\", \"Structural basis of the HSD17B11-FSP1 interface not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous physiological substrate and the direction of catalysis in vivo remain unresolved, as does whether HSD17B11's catalytic activity is required for its lipid-droplet scaffolding roles.\",\n      \"evidence\": \"No timeline study reconciles the in vitro steroid/retinoid activities with a defined in vivo metabolic role or links catalysis to the FSP1/GCKIII functions\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No knockout-phenotype linking enzymatic activity to organismal steroid or lipid metabolism\", \"Mechanism coupling LD localization to FSP1 stability undefined\", \"No experimentally determined structure\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 6]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [5, 10, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 10]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [6, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FSP1\", \"MST3\", \"STK25\", \"MST4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}